NasdaqGS:ABCLLife Sciences
AbCellera Biologics (ABCL) Signs Vertex Deal, Is The Stock Still Cheap?
AbCellera Biologics (NasdaqGS:ABCL) shares are in focus after the company announced a new collaboration with Vertex Pharmaceuticals to discover, develop, manufacture, and commercialize multispecific T cell engagers for autoimmune diseases.
See our latest analysis for AbCellera Biologics.
The Vertex deal lands at a time when AbCellera Biologics has shown mixed momentum, with a 7.53% 7 day share price return, a 28.89% 90 day share price return, and a 34.67% 1 year total shareholder return,...